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Abstract 
Background: Bleeding is the most frequent complication associated with extracorporeal membrane oxygenation 
(ECMO) support in critically ill patients. Nonetheless, risk factors for bleeding have been poorly described especially 
those associated with coagulation anomalies and anticoagulant therapy during ECMO support. The aim of this study 
is to describe bleeding complications in critically ill patients undergoing ECMO and to identify risk factors for bleeding 
events.
Methods: We retrospectively analysed ICU charts of adults who received either veno-venous (VV) or veno-arterial 
(VA) ECMO support in two participating ICUs between 2010 and 2013. Characteristics of patients with and without 
bleeding complications, as per the Extracorporeal Life Support Organisation (ELSO) definition, were compared, and 
the impact of bleeding complications on patient outcomes was assessed using survival analysis. Variables that were 
independently associated with bleeding, including daily clinical and biological variables during ECMO courses, were 
modelled.
Results: Of the 149 ECMO episodes (111 VA ECMO and 38 VV ECMO) performed in 147 adults, 89 episodes (60 %) 
were complicated by at least one bleeding event. The most common bleeding sources were: ECMO cannula (37 %), 
haemothorax or cardiac tamponade (17 %) and ear–nose and throat (16 %). Intra-cranial haemorrhage occurred in 
five (2.2 %) patients. Bleeding complications were independently associated with worse survival [adjusted hazard 
ratio (HR) 2.17, 95 % confidence interval (CI) 1.07–4.41, P = 0.03]. Higher activated partial thromboplastin time (aPTT) 
[adjusted odds ratio (OR) 3.00, 95 % CI 1.64–5.47, P < 0.01], APACHE III score [adjusted OR 1.01, 95 % CI 1.01–1.02, 
P = 0.01] and ECMO following surgery [adjusted OR 3.04, 95 % CI 1.62–5.69, P < 0.01] were independently associated 
with greater risk of bleeding occurrence. A similar association between bleeding and higher aPTT was found when 
non-post-surgical VA ECMO was considered separately.
Conclusions: Bleeding events based on the ELSO bleeding definition occurred in more than 60 % of ECMO episodes 
and were associated with hospital mortality. We identified higher aPTT prior bleeding as an independent risk factor for 
bleeding event, suggesting that better control of the aPTT (through a better control of either coagulopathy or antico-
agulation) may improve patients’ outcome.
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Background
Bleeding is one of the most frequent complications occur-
ring in patients undergoing extracorporeal membrane 
oxygenation (ECMO), occurring in approximately 30 % of 
patients receiving ECMO therapy [1–4]. Bleeding events 
independently impact on patient prognosis, including 
mortality [1, 2]. This association may be explained by the 
site of bleeding, with intra-cranial haemorrhage (ICH) 
identified in more than 40 % of non-survivors in patients 
treated with ECMO during the H1N1 flu outbreak [5].
Many factors that may place patients undergoing 
ECMO at higher risk of bleeding have been identified 
[6], and these can be classified into patient, treatment 
and circuit related. The systemic inflammatory response 
syndrome (SIRS) and contact between the patient’s 
blood with the ECMO circuit lead to activation of the 
coagulation cascade, with effects on fibrinolysis, throm-
bin formation and platelet function [6–8]. The results of 
these changes to haemostatic balance may be difficult 
to predict, with the coexistence of both thrombotic and 
haemorrhagic risks. Although use of bioline surface-
heparinised extracorporeal perfusion circuits reduces the 
risk of thrombosis, with decreases in inflammation, coag-
ulation activation and platelet consumption, anticoagu-
lation remains standard practice in patients undergoing 
ECMO to offset circuit-associated thrombotic risks [9, 
10]. Indeed, thrombotic events might complicate ECMO 
therapy with significant morbidity and mortality. Throm-
botic events have been identified in approximately 15 % 
of ECMO courses [11], but they are likely to be underdi-
agnosed and underreported [12].
A better knowledge of characteristics of bleeding dur-
ing ECMO is essential to improve management and out-
comes of patients undergoing ECMO. Studies on risk 
factors for haemorrhagic complications have predomi-
nantly been performed in paediatric patients or suffer 
limitations, including lack of standard bleeding defini-
tion and the timing of the study with many advances in 
ECMO circuit and care over the past decades [13, 14].
Therefore, we aimed to study bleeding complications 
in critically ill patients undergoing ECMO to define inci-
dence, consequences on patient prognosis and factors 
associated with increased bleeding risk.
Patients and methods
Study design
We conducted a retrospective study in two centres, the 
Alfred Hospital (Melbourne, Australia) and the Hospital 
of Besançon (France). The Alfred Hospital is a teaching 
hospital affiliated to Monash University, which provides 
heart and lung transplantation services for the states of 
Victoria, South Australia and Tasmania. It has an inten-
sive care unit (ICU) with a 45-bed capacity and is the 
referral centre for adult trauma and ECMO in Victoria. 
The Hospital of Besançon is a teaching hospital affiliated 
to the University of Franche-Comté; its 21-bed medical 
ICU has long-standing experience in ECMO support.
All adults admitted to ICU between January 2010 and 
June 2013 at the Alfred Hospital and between January 
2013 and December 2013 at the Hospital of Besançon 
and who underwent ECMO were included.
The study was approved by the Alfred Health Human 
Research Ethics Committee (202/11) and by the Ethics 
Committee of Besançon Hospital.
ECMO haemostatic practice
Both hospitals had anticoagulation protocols and local 
guidelines for haemostatic management for patients 
undergoing ECMO, and these protocols were similar for 
VV and VA ECMO. In both centres, systemic antico-
agulation with a heparin infusion targeting an activated 
partial thromboplastin time (aPTT) between 50 and 70 s 
was standard practice, unless patients were bleeding 
or at increased risk of bleeding (usually related to peri-
operative and traumatic injuries). Red blood cell (RBC) 
transfusion was given to maintain a haemoglobin (Hb) 
concentration above 8  g/dL. Prophylactic blood prod-
ucts were not routinely given for coagulation abnor-
malities, with the exception of severe thrombocytopenia 
(<50,000 platelets/mm3). In the case of bleeding, platelets 
were administered to maintain a platelet count ≥80,000/
mm3, fresh frozen plasma (FFP) to maintain the interna-
tional normalised ratio (INR) ≤1.5 or prothrombin (PT) 
>70  %, and cryoprecipitate or fibrinogen concentrate 
to maintain fibrinogen plasma concentration ≥1.5  g/L. 
Coagulation factor concentrates, antifibrinolytic agents 
(tranexamic acid), antithrombin III and protamine were 
administered when deemed appropriate by the intensiv-
ist in charge. Heparin was the anticoagulant of choice; 
however, alternatives (warfarin, lepirudin) were used if 
necessary. ECMO circuits were phosphorylcholine and 
heparin bonded in both centres. Circuit membrane was 
changed at the Alfred Hospital if there was evidence of 
systemic fibrinolysis presumed to be due to circuit or 
clot in the oxygenator and at both sites in cases of poor 
oxygenator function and increases in trans-oxygenator 
pressure. Proton pump inhibitors were routinely admin-
istered to ECMO patients. At the Alfred Hospital, both 
cannulae of VA and VV ECMO were percutaneously 
inserted, while at Hospital of Besançon cannula of VA 
ECMO was surgically inserted.
Clinical and biological data
Medical history and clinical charts were retrospectively 
reviewed, and the following data were collected: demo-
graphics, comorbidities, ICU and hospital admission 
Page 3 of 10Aubron et al. Ann. Intensive Care  (2016) 6:97 
and discharge dates, diagnosis and Acute Physiology and 
Chronic Health Evaluation (APACHE III) score at admis-
sion. Treatment with aspirin, clopidogrel or vitamin K 
antagonist, surgery or cardiopulmonary resuscitation 
prior to ECMO initiation was recorded. The Sequen-
tial Organ Failure Assessment (SOFA) scores prior to 
ECMO initiation and on the third day of ECMO were 
calculated. Requirement for renal replacement therapy 
(RRT), mechanical ventilation (MV) or intra-aortic bal-
loon pump while on ECMO were also collected. The daily 
highest and lowest values of the following biological data 
were recorded for each day on ECMO: Hb on formal full 
blood examination, platelet count, aPTT, INR, PT and 
fibrinogen level. The lowest temperature, the lowest value 
of arterial pH and ionised calcium, the highest D-dimer, 
urea, bilirubin and free Hb were also collected for each 
day on ECMO.
ECMO data
ECMO data included the commencement and cessation 
date, whether the ECMO was initiated in another hospi-
tal, the main indication for ECMO and the type of ECMO 
[veno-venous (VV) or veno-arterial (VA) including cen-
tral and peripheral VA ECMO]. The following data were 
also recorded: outcomes of ECMO, status at ICU and 
hospital discharge and location of hospital discharge.
Bleeding events and thromboembolic events
Daily information on blood product and haemostatic 
agent use, including type and dose of anticoagulant, was 
collected for the duration of ECMO.
Bleeding events were defined according to the Extra-
corporeal Life Support Organisation (ELSO) definition 
[15]: we defined a bleeding event if there was clinically 
overt bleeding recorded in the medical and/or nursing 
charts associated with either administration of 2 or more 
RBC units in 24 h or a drop in haemoglobin greater than 
2  g/L over 24  h, or if there was a haemothorax, central 
nervous system or retroperitoneal bleeding, or if bleed-
ing required an intervention. If there were consecutive 
days with the same primary source of bleeding as preced-
ing days, these were considered the same bleeding event. 
When a patient had more than one bleeding source on 
the same day, this was also recorded.
Thromboembolic complications, including deep 
venous thrombosis, ischaemic stroke, intra-cardiac 
thrombus, pulmonary embolism and membrane circuit 
clotting requiring membrane change, were collected 
from the medical record.
Statistical analysis
All analyses were performed using Stata 12.0 (Col-
lege Station, Texas). Descriptive statistics are reported 
as mean (standard deviation) or median (inter-quartile 
range, IQR) according to data distribution. Hypoth-
esis testing for patient level data was performed using 
Chi-square for categorical variables, Student’s t test for 
normally distributed data and Wilcoxon’s rank sum for 
non-normally distributed data. For comparisons between 
ECMO days with and without bleeding, to account 
for the repeated measures per patient (with bleeding 
recorded on each day of ECMO treatment), a repeated 
measures mixed model was performed for continuous 
variables and random effects logistic model for binomial 
variables. Mean and 95  % confidence interval (CI) are 
reported adjusted for repeated measures.
Survival curves were plotted using the Kaplan–Meier 
method, and groups were compared using the log-rank 
test. Multivariable analysis for predictors of survival 
was performed using a Cox proportional hazard regres-
sion model, including those variables that were associ-
ated with the outcome with a P < 0.2. As the relationship 
between bleeding and survival was time dependent (with 
bleeding occurring at different times during the course 
of ECMO treatment), bleeding variables were treated as 
time-varying covariates in the Cox proportional hazard 
models. The final models were assessed for proportional-
ity using the proportional hazards assumption test.
To investigate predictors of bleeding, multiple logistic 
regression modelling was performed. Initially, a back-
ward stepwise logistic model was performed, which only 
included variables recorded prior to the day of bleeding 
(e.g. highest aPTT on the day prior to the bleeding event, 
anticoagulation on the day prior to the bleeding event, 
etc.). aPTT was categorised into quartiles for the multi-
variable analysis. To account for the repeated measures 
per patient, variables that were found to be independently 
associated with the bleeding outcomes in the stepwise 
logistic model were then included in a multi-level logis-
tic regression model, with each patient now modelled as 
a random effect. Subgroup analyses were performed in 
patients undergoing non-post-surgical VA ECMO.
Results
Over the study period, 149 episodes of ECMO support, 
38 VV and 111 VA ECMO, were conducted in both 
hospitals (Alfred, n =  125, and Besançon, n =  24). The 
median duration of support was 8  days (first and third 
quartiles: 5–14) for the VV ECMO and 6 days (first and 
third quartiles: 4–10) for the VA ECMO. Characteristics 
of study cohort are given in Table 1.
Bleeding events
Overall there were 128 bleeding events (with a bleed-
ing event defined as consecutive days meeting the bleed-
ing definition with the same source of bleeding) over 203 
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Table 1 Comparison of ECMO episodes with and without bleeding events
Variable All episodes (n = 149) No bleeding (n = 60) Bleeding (n = 89) P
Age (year ± SD) 46.5 ± 14.9 44.5 ± 15.1 47.8 ± 14.7 0.18
Male sex 92 (62 %) 38 (63 %) 54 (61 %) 0.74
Weight (kg ± SD) 80.7 ± 22 80.7 ± 22 80.7 ± 22 1.00
APACHE III score ± SD 77.3 ± 33.6 70.1 ± 30 82.1 ± 35.2 0.03
Comorbidities
Immunosuppressed 34 (23 %) 8 (14 %) 26 (29 %) 0.027
Hepatic failure 3 (2 %) 2 (3 %) 1 (1 %) 0.34
Cirrhosis liver disease 2 (1.3 %) 0 (0 %) 2 (2 %) 0.25
Insulin dependent diabetes 7 (5 %) 3 (5 %) 4 (5 %) 0.87
Chronic respiratory failure 23 (16 %) 4 (7 %) 19 (21 %) 0.018
Chronic cardiovascular disease 38 (26 %) 14 (24 %) 24 (27 %) 0.66
Chronic renal failure 2 (1.3 %) 0 (0 %) 2 (2 %) 0.25
Indications for ECMO
Acute cardiomyopathy 20 (13 %) 12 (20 %) 8 (9 %) 0.05
AMI 28 (19 %) 9 (15 %) 19 (21 %) 0.33
Chronic cardiomyopathy 14 (9 %) 8 (13 %) 6 (7 %) 0.18
Heart transplant 16 (11 %) 4 (7 %) 12 (13 %) 0.19
Lung transplant 15 (10 %) 3 (5 %) 12 (13 %) 0.09
Pneumonia 27 (18 %) 16 (27 %) 11 (12 %) 0.03
Post CAGS or valve surgery 9 (6 %) 1 (2 %) 8 (9 %) 0.07
Other 20 (13 %) 7 (12 %) 13 (15 %) 0.61
Post-surgical ECMO 39 (26 %) 4 (7 %) 35 (39 %) <0.001
Transplantation prior 33 (22 %) 8 (13 %) 25 (28 %) 0.033
Cardiac arrest before 39 (26 %) 14 (23 %) 25 (28 %) 0.52
Medication prior ECMO
Aspirin 35 (24 %) 13 (22 %) 22 (26 %) 0.59
Clopidogrel 17 (12 %) 5 (8 %) 12 (14 %) 0.32
Warfarin 16 (11 %) 4 (7 %) 12 (14 %) 0.16
ECMO started in another hospital 40 (27 %) 20 (33 %) 20 (22 %) 0.14
ECMO type
VA ECMO 111 (74 %) 40 (67 %) 71 (80 %) 0.07
VV ECMO 38 (26 %) 20 (33 %) 18 (20 %) 0.07
Days on support, median [IQR] 7 [5–11] 6 [5–10] 8 [5–12] 0.09
Centre Alfred Hospital 128 (86 %) 52 (87 %) 76 (85 %) 0.83
RRT at any time 60 (43 %) 18 (31 %) 42 (51 %) 0.02
MV at any time 145 (97 %) 57 (95 %) 88 (99 %) 0.15
SOFA score prior ECMO median [IQR]
Total 10 [7–13] 9 [7–12] 11 [9–14] 0.01
SOFA respiratory 3 [2–4] 3 [2– 4] 3 [1–4] 0.95
SOFA coagulation 0 [0–1] 0 [0–1] 1 [0–2] 0.17
SOFA liver 0 [0–2] 0 [0–1] 1 [0–2] 0.02
SOFA cardiovascular 4 [4–4] 4 [3–4] 4 [4–4] 0.02
SOFA neurology 1 [0–2] 0 [0–1] 1 [0–3] 0.02
SOFA renal 1 [0–3] 1 [0– 2] 1 [0–3] 0.21
Blood product use during ECMO
Median RBC unit (IQR) 6 [2–14] 2 [0.5–4] 12 [6–19] <0.01
Median PLT doses (IQR) 1 [0–3] 0 [0–1] 2 [0–5] <0.01
Median FFP unit (IQR) 2 [0–6] 0 [0–1] 5 [1–10] <0.01
Median cryoprecipitate (IQR) 0 [0–0] 0 [0–0] 0 [0–1] <0.01
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ECMO days with 224 bleeding sources identified. Of 
the 149 ECMO episodes, 58 (39 %) had one, 14 (9 %) had 
two, 9 (6 %) had three, 5 (3 %) had four and 3 (2 %) had 
five bleeding events during the ECMO course. The median 
time to the first bleeding event from starting ECMO was 
4  days (first and third quartiles: 0–8  days). Of the 224 
sources of bleeding identified, the three most frequent 
were ECMO cannula, post-cardiothoracic surgical hae-
mothorax or tamponade, and ear–nose and throat (ENT) 
haemorrhage (Fig.  1). Intra-cranial haemorrhage (ICH) 
occurred in 5 patients (2.2  %) and was fatal in all cases. 
There were 67 specific haemostatic interventions for bleed-
ing in 43 ECMO episodes that included surgical interven-
tion (n = 56), angiography (n = 5), gastroscopy (n = 4) and 
bronchoscopy (n = 2). Tranexamic acid was administered 
in 15 bleeding events, activated recombinant factor VII in 3 
events and prothrombin complex concentrate and fibrino-
gen concentrate in 5 and 2 bleeding events, respectively.
Eighty-nine ECMO episodes (60  %) were complicated 
by at least one bleeding event. There were no differences 
in patient demographics and comorbidities between 
those who experienced bleeding complications and those 
who did not (Table  1). When haemorrhagic complica-
tions occurred during ECMO, patients were more likely 
to have surgery prior to ECMO (39 vs. 7  %, P  <  0.001), 
had greater illness severity at ECMO initiation with a 
median SOFA score of 11 (first and third quartiles: 9–14) 
vs. 9 (first and third quartiles: 7–12) (P = 0.01) and more 
often required RRT (64 vs. 35 %; P < 0.01). Antiplatelet 
therapy or warfarin prior to ECMO was not associated 
with bleeding events in univariate analysis, nor was the 
duration of ECMO.
When considering the days on ECMO individually, 
1144 days on ECMO were free of bleeding while 203 met 
the ELSO definition of bleeding. Lower Hb [mean 87 g/L 
(95  % CI 84–89) vs. 93  g/L (95  % CI 90–95); P  <  0.01], 
lower arterial pH [mean 7.30 (95 % CI 7.28–7.32) vs. 7.35 
(95  % CI 7.33–7.36); P  <  0.01], lower ionised calcium 
[mean 1.02 mmol/L (95 % CI 1.01–1.05) vs. 1.09 mmol/L 
(95  % CI 1.07–1.10); P  <  0.01] and higher aPTT [mean 
90 s (95 % CI 81–98) vs. 71 s (95 % CI 67–76); P < 0.01] 
recorded on the day prior to bleeding were associated 
with bleeding occurrence when considering all patients 
with and without heparin (Table 2). A lower proportion 
of patients with bleeding had received heparin on the 
Data presented as n (%) categorical variables and median (interquartile range) for nonparametric variables
“Post-surgical ECMO” includes any surgery (CAGS and other)
ECMO extracorporeal membrane oxygenation, APACHE III score Acute Physiology and Chronic Health Evaluation III score, AMI acute myocardial infarction, CAGS 
coronary artery graft surgery, VA ECMO veno-arterial ECMO, VV ECMO veno-venous ECMO, RRT renal replacement therapy, MV mechanical ventilation, SOFA Sequential 
Organ Failure Assessment, RBC red blood cell unit, FFP fresh frozen plasma, PLT platelets bag, ICU intensive care unit, LOS length of stay
Table 1 continued
Variable All episodes (n = 149) No bleeding (n = 60) Bleeding (n = 89) P
Other adverse events
Ischaemic stroke 4 (2.7 %) 1 (2 %) 3 (3 %) 0.53
Membrane change 16 (11 %) 6 (10 %) 10 (11 %) 0.81
Limb ischaemia any stage 11 (7 %) 2 (3 %) 9 (10 %) 0.12
Outcomes
Weaned off ECMO 95 (64 %) 42 (70 %) 53 (60 %) 0.19
Never weaned 36 (24 %) 10 (17 %) 26 (29 %) 0.08
Bridge to other assistance 18 (12 %) 8 (13 %) 10 (11 %) 0.70
Median (IQR) ICU LOS (days) 17 [9–28] 13.5 [8–23] 16 [9–28] 0.18
Median (IQR) hospital LOS (days) 36.5 [15–56] 27.5 [13.5–36.5] 36.5 [15–56] 0.04
ICU status, alive 101 (68 %) 45 (75 %) 56 (63 %) 0.12
Hospital status, alive 99 (66 %) 45 (75 %) 54 (61 %) 0.07





















Fig. 1 Bleeding sources. Results are expressed as absolute values 
(n). There were 224 sources identified in 128 haemorrhage events. 
Lines include central venous catheter; ENT ear–nose and throat, GI 
gastrointestinal
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previous day compared to those without bleeding; how-
ever, those who did receive it and who were bleeding 
had higher aPTT compared to the non-bleeding patients 
[mean 86  s (95  % CI 76–95) vs. 69  s (95  % CI 64–73); 
P < 0.01]. Intra-aortic balloon pump was present in 4 % 
(n = 6) of days with bleeding compared with 1 % (n = 12) 
of days without bleeding. Type of ECMO was also associ-
ated with bleeding (Table 2).
Four patients had an ischaemic stroke (2.7  %), limb 
ischaemia occurred in 11 patients (7.4 %), and membrane 
was changed for 16 circuits. There was no difference in 
thrombotic events between bleeding and non-bleeding 
patients. None of the patients who received tranexamic 
acid or activated factor VII were diagnosed with throm-
botic complications.
Factors associated with bleeding
After adjusting for repeated measures in the same 
patient, factors that were significantly associated with 
increased risk of bleeding were: higher aPTT on the day 
prior, with a significant association for the highest quar-
tile compared to the lowest quartile, higher APACHE III 
score and post-surgical ECMO. Variables associated with 
lower risk of bleeding were anticoagulation on the day 
prior to the event (Table  3). ECMO type was not asso-
ciated with the risk of bleeding in the adjusted model. 
When considering only the 75 non-post-surgical VA 
ECMO episodes, higher aPTT on the day prior remained 
associated with bleeding [adjusted OR 3.24 (95  % CI 
1.11–9.44); P =  0.03] (Table  4). In this subgroup analy-
sis, the daily lowest temperature was also associated with 
bleeding occurrence. 
Independent predictors for survival
Bleeding was associated with worse survival [HR 3.04 
(95  % CI 1.58–5.89); P  <  0.01] on univariate analysis. 
When adjusting for other variables predictive of sur-
vival, bleeding was associated with worse survival [HR 
2.17 (95 % CI 1.07–4.41); P = 0.03] as given in Table 5. 
The other variables associated with worse survival 
were SOFA score at ECMO initiation [HR 1.10 (95  % 
CI 1.01–1.20); P  =  0.03] and indication for ECMO 
(Table  5). When considering only patient undergoing 
non-post-surgical VA ECMO, bleeding was also associ-
ated with worse survival [HR 3.05 (95 % CI 1.11–8.38); 
P = 0.03] (Table 6).
Table 2 Comparison of biological and transfusion characteristics of days on ECMO with and without bleeding events
Hb haemoglobin, INR international normalised ratio, Fg fibrinogen, aPTT activated partial thromboplastin time, RRT renal replacement therapy, IABP intra-aortic 
balloon pump, VA ECMO veno-arterial ECMO
a Mean (95 % CI) adjusted for repeated measures presented for continuous variables and number (%) for categorical variables. P values are adjusted for repeated 
measures
b Values are for day prior to bleeding event when considering ECMO days with bleeding
Variablea ECMO days without bleeding (n = 1144) ECMO days with bleeding (n = 203) P
Lowest Hb (g/dL)b 93 (90–95) 87 (84–89) <0.01
Lowest platelet count (×109 cells/L)b 125 (115–134) 131 (122–141) 0.15
Highest INRb 1.6 (1.5–2.0) 1.9 (1.7–2.0) 0.14
Lowest Fg (g/L)b 4.0 (3.8–4.3) 3.9 (3.7–4.2) 0.59
Highest aPTT (s)b 71 (67–76) 90 (81–98) <0.01
Lowest arterial pHb 7.35 (7.33–7.36) 7.30 (7.28–7.32) <0.01
Lowest temperature (°C)b 36.1 (35.9–36.2) 36.1 (35.9–36.2) 0.85
Highest urea (mmol/L)b 11.1 (10.4–11.7) 11.4 (10.6–12.2) 0.40
Lowest corrected calcium (mmol/L)b 1.09 (1.07–1.10) 1.02 (1.01–1.05) <0.01
Highest free haemoglobinb 0.07 (0.06–0.08) 0.07 (0.05–0.10) 0.65
RRTb 461 (40 %) 76 (37 %) 0.43
Bilirubinb 22.6 (19.6–26.0) 22.1 (20.0–24.4) 0.67
Anticoagulation
Heparin infusionb 816 (71 %) 106 (52 %) <0.01
Hours on heparin per dayb 22 (19–24) 18 (15–20) 0.04
Highest aPTT if receiving heparin (s)b 69 (64–73) 86 (76–95) <0.01
Daily dose heparin if receiving heparin (unit)b 19,256 (17,292–21,219) 21,400 (19,187–23,614) 0.06
Centre Alfred Hospital 1085 (95 %) 181 (89 %) 0.10
Max membrane gradient (mmHg) 21 (19–23) 20 (17–22) 0.55
VA ECMO 737 (64 %) 164 (81 %) <0.01
Type of access if VA ECMO, peripheral 697 (94 %) 146 (89 %) 0.04
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Discussion
Bleeding complications, as defined by ELSO, occurred 
in more than half of critically ill patients undergoing 
ECMO and were strongly and independently associ-
ated with hospital mortality. The most frequent bleeding 
sources identified in our study included ECMO cannula, 
post-cardiothoracic surgery site and ENT. We found 
that illness severity and higher aPTT on the day prior 
to bleeding onset were independently associated with 
bleeding, while anticoagulant administration on the day 
prior was associated with a lower risk of bleeding. Our 
results emphasise the importance of further studies 
on coagulation abnormalities in this population.
Comparison with available literature
We found that 60 % of ECMO courses were complicated 
by bleeding, which is higher than previously reported 
bleeding rates. This difference may be due to differences 
in bleeding definitions [3, 11]. Bleeding events in ECMO 
patients, when reported in the literature, are either not 
clearly defined or reported on the basis of organ site 
involved, death due to bleeding, requirement for surgi-
cal intervention or using only RBC transfusion as a sur-
rogate of bleeding [2, 11, 13]. Extracorporeal Life Support 
Organization (ELSO) guidelines recently provided defi-
nition criteria for bleeding complications [15]. Although 
this definition has not commonly been used in studies 
related to bleeding in ECMO, it may allow and facilitate 
comparison between findings of ours and future studies.
We found that post-surgical bleeding and ECMO can-
nula were the most common sources of bleeding in 
patients undergoing ECMO, as previously reported [1, 
11, 16]. However, ENT has not commonly been reported 
as a source of bleeding in this patient population. Sever-
ity of ENT bleeding may be difficult to estimate, and its 
Table 3 Factors independently associated with bleeding in multivariable analysis
Analysis includes 1125 days with complete data
aPTT activated partial thromboplastin time, APACHE III score Acute Physiology and Chronic Health Evaluation III score
a aPTT < 46 s is the reference
Variable Adjusted odds ratio 95 % confidence interval P
Previous-day aPTTa
≥46 and ≤55 s 1.35 0.73–2.49 0.33
≥56 and ≤69 s 1.45 0.75–2.82 0.26
≥70 s 3.00 1.64–5.47 <0.01
Previous-day anticoagulation 0.40 0.24–0.66 <0.01
APACHE III score 1.01 1.01–1.02 0.01
Post-surgical ECMO 3.04 1.62–5.69 <0.01
Table 4 Factors independently associated with  bleeding 
in non-post-surgical VA ECMO (N = 75) (adjusted for ECMO 
indication and severity)
aPTT activated partial thromboplastin time, APACHE III score Acute Physiology 
and Chronic Health Evaluation III score
a aPTT < 46 s is the reference






≥46 and ≤55 s 2.03 0.68–6.10 0.30
≥56 and ≤69 s 1.32 0.41–4.27 0.47







APACHE III score 1.03 1.01–1.04 <0.01
Table 5 Factors independently associated with  reduced 
survival
aPTT activated partial thromboplastin time, APACHE III score Acute Physiology 
and Chronic Health Evaluation III score, SOFA Sequential Organ Failure 
Assessment, AMI acute myocardial infarction





Bleeding on one or 
more days
2.17 1.07–4.41 0.03
Hospital 2.14 0.92–4.94 0.08
APACHE III score 0.99 0.98–1.01 0.39
SOFA score prior to 
ECMO
1.10 1.01–1.20 0.03
Indication for ECMO (lung transplant reference)







Heart transplant 7.26 0.96–55.23 0.06
Cardiac surgery 9.07 1.06–77.28 0.04
Pneumonia 3.68 0.45–30.12 0.22
Other 12.11 1.73–84.41 0.01
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haemodynamic consequences may be less acute than 
other bleeding sites. Nonetheless, ENT bleeding is 
important to diagnose because it may require specific 
investigation for primary haemostatic disorders, such as 
platelet function abnormalities and von Willebrand dis-
ease, and specific treatment including local haemostatic 
packing [17]. In our study, ICH complicated ECMO 
in 2.2  % of cases. This figure is comparable to those 
reported by Paden et  al. but lower than those found in 
other cohorts [5, 11]. ICH may also be underestimated in 
our study, as CT brain scans and post-mortem examina-
tion were not routinely performed.
Risk factors for bleeding previously studied include 
parameters available at ECMO initiation (i.e. demo-
graphics, ECMO characteristics, patient characteristics 
at ECMO initiation). There are few reports evaluating 
bleeding risk factors measured during ECMO treatment. 
A few decades ago, Kasirajan et al. reported an associa-
tion between ICH and platelet count [14]. In our study, 
we did not find an independent association between 
thrombocytopenia and haemorrhage, possibly because 
the median platelet count remained relatively high and 
possibly because of the low rate of the ICH. The same 
authors reported an association between ICH and hepa-
rin therapy. However, information about heparin regimen 
and coagulation results were not provided [14]. In our 
study, the fact that a lower proportion of patients with 
bleeding had received heparin on the previous day com-
pared to those without bleeding may be explained if the 
onset of bleeding was prior to when the patients met the 
ELSO bleeding definition, resulting in clinicians ceasing 
heparin infusion. It could also be explained by physicians 
selecting patients at lower risk of bleeding for therapeutic 
anticoagulation, and that patients who remain on hepa-
rin have proven their tolerance to anticoagulation with-
out bleeding. However, we also found that the intensity 
of anticoagulation (as measured by aPTT) was associated 
with increased bleeding risk (with increasing OR with 
increasing aPTT categories), suggesting that high aPTT 
in anticoagulated patients are deleterious. This supports 
the need for further research on anticoagulation and risk 
of bleeding in this population. In a recent prospective 
observational study using thromboelastography (TEG) 
to evaluate anticoagulation profile during 32 VV ECMO 
episodes, heparin therapy and aPTT were associated 
with a reaction time of >90 min (“flat-line” profile); these 
results also emphasise the need for optimisation of anti-
coagulation management in this population [18]. Both 
ECMO and cardiac surgery lead to decrease in fibrino-
gen level [7, 19]. Association between low fibrinogen 
level and bleeding events has been recently reported in 
paediatrics ECMO and in surgical setting [20, 21]. The 
key role of coagulation abnormalities has been suggested 
indirectly in other studies, in which a benefit of carefully 
monitoring and treating coagulopathy in ECMO patients 
was found [19, 22].
Patients who undergo VA ECMO have different comor-
bidities, underlying diseases and anticoagulant require-
ment compared to patients who undergo VV ECMO. 
While VA  ECMO was associated with more bleeding 
days in the univariate analysis, this association did not 
remain in the adjusted analysis; however, we may have 
been underpowered to detect a difference if one did 
exist. Likewise, there were some differences in bleeding 
risk according to diagnosis; however, this did not remain 
associated in the adjusted analysis. Finally, with a high 
incidence of post-surgical VA ECMO (32  %), we may 
have missed an association between type of ECMO and 
bleeding risk despite the absence of colinearity between 
these post-surgical ECMO and ECMO type.
Implications of study findings and future research
This risk of bleeding should be taken into consideration 
in clinical management, including invasive procedures 
in this population. Although this is a retrospective study 
with the limitations secondary to this design, our findings 
on the association between coagulation abnormalities 
and bleeding in adults on ECMO highlight the impor-
tance of closely monitoring coagulation and bleeding in 
this population. Having local haemostatic guidelines to 
manage bleeding and non-bleeding patients undergoing 
ECMO should be a priority for ECMO centres.
Prospective studies evaluating optimal haemostatic 
treatment, including blood components, intensity of 
anticoagulation, use of tranexamic acid, concentrate 
Table 6 Factors independently associated with  reduced 
survival in  the sub group of  patients undergoing non-
post-surgical VA ECMO (N = 75)
aPTT activated partial thromboplastin time, SOFA Sequential Organ Failure 
Assessment, AMI acute myocardial infarction





Bleeding on one or 
more days
3.05 1.11–8.38 0.03
Hospital 1.41 0.47–3.62 0.47
SOFA score prior to 
ECMO
1.11 0.98–1.26 0.11








Heart transplant 0.86 0.16–4.69 0.86
Other 0.51 0.19–1.42 0.20
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of coagulation factors and antithrombin III with their 
effects on bleeding and thromboembolic complications 
are warranted. Beside coagulation monitoring by throm-
boelastography might also be beneficial in this high-risk 
population [18, 23].
It would also be meaningful to perform a larger pro-
spective study considering separately fatal bleeding as an 
outcome.
Strengths and limitations
Our work addresses an important issue in the manage-
ment of patients on ECMO, as bleeding complications 
remain common and associated with poor prognosis. It 
studies clinical, biological and therapeutic parameters 
that may be risk factors for bleeding complications. We 
used a clear definition of bleeding events, thereby ensur-
ing accuracy of our outcome measure and allowing com-
parisons with other studies. Inclusion of patients from 
two ECMO centres provides external validity to our 
results. Time-dependent survival analysis enables iden-
tification of parameters not only at ECMO initiation but 
also during the ECMO course.
Our study does, however, suffer several limitations. 
Due to the retrospective study design, we could only 
explore associations between risk factors and bleeding 
outcomes and cannot make any conclusions regarding 
causation. We also cannot exclude the possibility of con-
founding by unmeasured factors, for example cannula-
tion method. The retrospective design may also lead to 
misclassification of bleeding events. However, the defi-
nition of bleeding that we used relies on transfusion vol-
umes, bleeding at specific sites and/or requirement for 
intervention, all of which could be objectively measured 
from electronic laboratory data and medical records. As 
it was not possible to identify the time at which bleed-
ing started, we analysed association between variables 
collected on the preceding day. Furthermore, we could 
not perform relevant statistical analysis considering sub-
groups of either patients undergoing VV ECMO only or 
post-surgical ECMO because of their small sample size. 
Finally, thrombosis complications are likely to be under-
reported because of the retrospective design.
Conclusions
In conclusion, our study shows that bleeding events 
as defined by the ELSO remain a common and serious 
complication in patients undergoing ECMO, with 60  % 
of ECMO courses complicated by at least one bleeding 
complication. Bleeding while on ECMO is independently 
associated with hospital mortality. Among identified risk 
factors for bleeding event, besides patient severity, coag-
ulation anomalies are the only identified which may be 
targeted with interventions. These findings highlight the 
importance of further research to determine the safest 
haemostatic management in this population.
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